- Trials with a EudraCT protocol (241)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
241 result(s) found for: Clear Cell Renal Cell Carcinoma.
Displaying page 1 of 13.
EudraCT Number: 2012-000473-23 | Sponsor Protocol Number: RETRY | Start Date*: 2012-05-29 | |||||||||||
Sponsor Name:GIOM - Gruppo Italiano Oncologia Nefrologica | |||||||||||||
Full Title: PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER | |||||||||||||
Medical condition: Metastatic renal cancer thrid-line therapy already treated in fist-line therapy with Sunitinib. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000127-32 | Sponsor Protocol Number: ROPETAR | Start Date*: 2011-11-03 | |||||||||||||||||||||
Sponsor Name:Werkgroep Immunotherapie Nederland voor Oncologie | |||||||||||||||||||||||
Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second lin... | |||||||||||||||||||||||
Medical condition: Advanced or metastatic clear cell renal cancer. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001337-13 | Sponsor Protocol Number: CRAD001LIC34T | Start Date*: 2012-08-17 | |||||||||||
Sponsor Name:APRO | |||||||||||||
Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront rotations between sunitinib and everolimus versus sequential treatment of first line sunitinib and second line everoli... | |||||||||||||
Medical condition: Metastatic clear cell renal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004011-12 | Sponsor Protocol Number: SOGUG-2016-A-IEC(REN)-10 | Start Date*: 2017-03-29 | |||||||||||
Sponsor Name:SOGUG (Spanish Oncology Genitourinary Group) | |||||||||||||
Full Title: Phase II study to evaluate efficacy and safety of sunitinib therapy in patients with metastatic renal clear cell carcinoma who have progressed to first-line immunotherapy treatment (INMUNOSUN Study) | |||||||||||||
Medical condition: metastatic renal clear cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004699-38 | Sponsor Protocol Number: RCCC10 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Klinikum der Universität Regensburg | |||||||||||||
Full Title: A prospective phase I/II, one-arm, multi-center, open label study of pioglitazone in combination with sorafenib and low dose IFN alpha in metastatic, non-resectable renal clear cell carcinoma | |||||||||||||
Medical condition: To investigate the effect of an anti-inflammatory therapy consisting of pioglitazone (Actos) in combination with an angiostatic treatment with sorafenib (Nexavar) and Interferin-Alpha (Roferon) on ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019726-14 | Sponsor Protocol Number: CRO-2010-01 | Start Date*: 2010-09-20 | |||||||||||
Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO | |||||||||||||
Full Title: SORAFENIB IN ELDERLY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (SERCC STIDY). IMPACT OF ADVERSE EVENTS MANAGEMENT IN ELDERLY mRCC PATIENTS TREATED WITH SORAFENIB. | |||||||||||||
Medical condition: PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AGED >/= 65 YRS | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000353-38 | Sponsor Protocol Number: WX-2003-07-HR | Start Date*: 2004-12-20 | |||||||||||
Sponsor Name:Wilex AG | |||||||||||||
Full Title: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence | |||||||||||||
Medical condition: Renal cell carcinoma of the clear cell type after nephrectomy and no evidence of residual disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) ES (Ongoing) GB (Completed) CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003054-28 | Sponsor Protocol Number: P070104 | Start Date*: 2007-10-17 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude des marqueurs biologiques, histologiques et d’imagerie dans le traitement de 1ère ligne du carcinome à cellules claires du rein en situation métastatique par Sunitinib avant et après néphrec... | |||||||||||||
Medical condition: Carcinome à cellules claires du rein en situation métastatique. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001211-31 | Sponsor Protocol Number: RG_10-177 | Start Date*: 2012-02-24 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02) | |||||||||||||
Medical condition: Clear cell renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000928-71 | Sponsor Protocol Number: GOIRC02/2008-TWIST | Start Date*: 2008-11-14 | |||||||||||||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA | |||||||||||||||||||||||
Full Title: TWIST. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008 | |||||||||||||||||||||||
Medical condition: Patients with advanced non-clear Cell Renal Carcinoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003870-16 | Sponsor Protocol Number: AlloTor | Start Date*: 2008-09-22 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: A PILOT STUDY OF SEQUENTIAL, NON-MYELOABLATIVE HLA-IDENTICAL SIBLING DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWED BY IV TEMSIROLIMUS IN PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENA... | |||||||||||||
Medical condition: PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENAL CELL CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000589-47 | Sponsor Protocol Number: 3475-427 | Start Date*: 2016-09-14 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427) | |||||||||||||
Medical condition: Renal cell carcinoma (clear cell & non-clear cell), or kidney cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) ES (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004548-35 | Sponsor Protocol Number: 15081982 | Start Date*: 2010-08-20 | |||||||||||
Sponsor Name:Radboud university nijmegen medical centre | |||||||||||||
Full Title: PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER | |||||||||||||
Medical condition: Patients with metastatic clear cell renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011669-10 | Sponsor Protocol Number: ARQ 197-204 | Start Date*: 2009-09-18 | |||||||||||||||||||||
Sponsor Name:ArQule, Inc. | |||||||||||||||||||||||
Full Title: A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Associated Tumors | |||||||||||||||||||||||
Medical condition: Microphthalmia Transcription Factor Associated Tumors: Clear cell sarcoma Alveolar soft part sarcoma Translocation associated renal cell carcinoma (Renal cell ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000493-56 | Sponsor Protocol Number: PIM4973g | Start Date*: 2011-09-15 | |||||||||||||||||||||
Sponsor Name:GENENTECH, Inc. | |||||||||||||||||||||||
Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0980 VERSUS EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE PROGRESSED ON OR FOLLOWING VEGF-TARGETED THERAPY | |||||||||||||||||||||||
Medical condition: METASTATIC RENAL CELL CARCINOMA | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) DE (Completed) GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022459-45 | Sponsor Protocol Number: IMA901-301 | Start Date*: 2010-12-15 | ||||||||||||||||
Sponsor Name:immatics biotechnologies GmbH | ||||||||||||||||||
Full Title: A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma | ||||||||||||||||||
Medical condition: The study population consists of HLA-A*02-positive metastatic and/or locally advanced RCC patients with histology of the clear-cell type who are aged 18 years or older and have a favorable or inter... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) GB (Completed) NL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005132-26 | Sponsor Protocol Number: CA209-025 | Start Date*: 2012-09-11 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther... | |||||||||||||||||||||||
Medical condition: Advanced or metastatic (medically or surgically unresectable) clear-cell Renal Cell Carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) DE (Completed) IT (Completed) AT (Completed) HU (Completed) CZ (Completed) DK (Completed) ES (Completed) NO (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003065-15 | Sponsor Protocol Number: VEG115232 | Start Date*: 2013-04-17 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib | ||||||||||||||||||
Medical condition: advanced or metastatic Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002957-67 | Sponsor Protocol Number: CA209-010 | Start Date*: 2011-11-23 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic T... | ||||||||||||||||||
Medical condition: Advanced/Metastatic renal cell carcinoma with a clear cell component | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000282-35 | Sponsor Protocol Number: BO17705 | Start Date*: 2004-09-29 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... | |||||||||||||
Medical condition: Metastatic clear cell renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.